A third of Australians experience jet lag-like symptoms associated with using tablets and laptops in the hour before they go to bed, a new study has found. By Anna Patty, Sydney Morning Herald
Results from the large multicenter iSPOT-A study have been published which not only suggest gender differences in brain activity in ADHD but also activity which may or may not respond to Psychostimulants
Important findings from a meta-analysis of 10 randomized-controlled studies on Neurofeedback demonstrate positive effects and long-term benefit of Neurofeedback in ADHD compared to medications
neuroCare provides safe and well-researched therapies for ADHD, depression, sleep problems, chronic pain and for rehabilitation, without the need for medication. At our neuroCare clinics we achieve this by integrating the work of clinicians with leading neuromodulation technology and by personalising the therapy. neuroConn is our technology brand, a global leader and industry pioneer in non-invasive neuromodulation. At neuroCademy we educate clinicians about neuromodulation and how to apply it in clinical practice and we evaluate outcomes and do research to further the quality of our care delivery.
Everything we do, think or feel is a memorised pattern in our brain or muscle memory. By harnessing the human brain’s plasticity, neuromodulation helps to reprogram those patterns by training our mind to more positive behaviour or for better cognitive performance. Behavourial, cognitive or motor disturbances can be treated faster and more efficiently when neurotechnology and the therapist work in synergy. Our therapy programs can be completed in as little as 3 months, with an average of 20 - 30 consultations needed to achieve lasting outcomes. With our personalised approach in our clinics we achieve average response rates of more than 70% for patients presenting with ADHD or Depression - something we are truly proud of.
At neuroCare, we also apply neurotechnologies in the diagnosis of mental disorders, allowing the therapist to personalise the treatment to the patient’s individual need - this is called prognostics. Most current treatments in mental health or neurology, particularly psychopharmaceuticals, still rely on a one-size-fits-all approach. Individual differences are ignored even though not all patients have the same underlying cause for their symptoms. This is why neuroCare has become a leader in the fast-growing neurotherapy market.
Psychiatry has traditionally been one of the only medical fields which has not been able to take a close look at the organ it is treating. With recent advances in technologies and diagnostic measures, practitioners in mental health now have access to innovative tools to make more informed assessments of the individual client they see.
At neuroCare, our therapists are trained to use these tools and have been supervised by leading neuroscientists and practitioners to make an informed and holistic assessment of a client’s presenting symptoms.
Our training courses are designed to instruct clinicians, academics and researchers in the use of neuromodulation technology, with a goal to apply these techniques in clinical practices or research settings. Under the guidance of our expert trainers, students receive substantial hands-on experience with rTMS, tDCS and neurofeedback technology and its application. Over the last 10 years we have trained more than 1,000 professionals from over 30 countries in the use of neuromodulation techniques. We have continually received outstanding feedback from our trainees, with an average evaluation of 8.9/10.
Learn more about our training courses
For more than ten years the neuroConn brand has been associated with practice-oriented medical technology used in neuroscience and clinical research, as well as in the diagnosis and treatment of neuropsychological disorders. In close cooperation with leading research institutions and clinics worldwide, neuroConn technology is designed following the latest medical research standards. In this way we provide users with standardised and clinically evaluated protocols in transcranial Electrical Stimulation (tDCS, tACS, tRNS) as well as Neurofeedback of Slow Cortical Potentials.
Learn more about our product range
